President’s Letter | September 2022
From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
09/27/2022
President’s Letter | September 2022
From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
|
09/27/2022
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
|
09/27/2022
AIM Welcomes Michelle Bessett as New Director of National Walks & Events
by Mara Klecker Michelle Bessett has always loved working with and helping other people. As AIM at Melanoma’s new Director…
|
09/16/2022
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
(NEWS PROVIDED BY Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
|
09/13/2022
Spirituality and Cancer Care With Michael Eselun, BCC
When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the…
|
09/13/2022
ESMO: TIL therapy improves on Yervoy in melanoma trial
(NEWS PROVIDED BY Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
|
09/12/2022
Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
|
09/11/2022
Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma
Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
|
09/06/2022
Survivor Spotlight: Erich & Jenn Djordjevic
By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
|
09/06/2022
Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor
By Mara Klecker Bev Johnson figured the abnormal bleeding she was experiencing was a side effect of her IUD losing…
|
Recent Posts
Jan. 27, 2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
Jan. 26, 2023
A Letter From Our Vice President | January 2023
Jan. 26, 2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
Jan. 26, 2023
What Makes AIM’s IMTBC Even More Valuable
Jan. 11, 2023